Investors consortium completed the $700m Series C round in Abogen Biosciences.

Investors consortium completed the $700m Series C round in Abogen Biosciences, a Covid vaccine developer. Investors in the round included Temasek, Invesco Developing Markets Fund, Loyal Valley Capital, GL Ventures, Yunfeng Capital, Lilly Asia Ventures and Boyu Capital and more. "We are grateful to the strong support from all of our investors, and I would also like to thank my team and collaborators for their incredible work and vigorous efforts in fighting COVID-19. We are leaders in mRNA therapy, harnessing the potential of this powerful and complex technology to create medicines that fulfill the unmet medical needs in an effort to enhance the health and extend the lives of patients with both rare and common diseases. With this new round of financing, we look forward to helping the world fight the rapidly changing global pandemic by accelerating our COVID-19 vaccine product development to improve its adaptiveness, and to recruiting the best industry talents to support our growth at all levels," Dr. Bo Ying, Abogen Founder and CEO.